EP2356109A4 - Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d autres maladies - Google Patents

Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d autres maladies

Info

Publication number
EP2356109A4
EP2356109A4 EP09820030A EP09820030A EP2356109A4 EP 2356109 A4 EP2356109 A4 EP 2356109A4 EP 09820030 A EP09820030 A EP 09820030A EP 09820030 A EP09820030 A EP 09820030A EP 2356109 A4 EP2356109 A4 EP 2356109A4
Authority
EP
European Patent Office
Prior art keywords
pain
diseases
compositions
methods
alcohol use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP09820030A
Other languages
German (de)
English (en)
Other versions
EP2356109B1 (fr
EP2356109A2 (fr
Inventor
Jay Jie-Qiang Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VM DISCOVERY Inc
Original Assignee
VM DISCOVERY Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK16187663.6T priority Critical patent/DK3135672T3/da
Application filed by VM DISCOVERY Inc filed Critical VM DISCOVERY Inc
Priority to PL09820030T priority patent/PL2356109T3/pl
Priority to EP16187663.6A priority patent/EP3135672B9/fr
Priority to PL16187663T priority patent/PL3135672T3/pl
Priority to SI200931622A priority patent/SI2356109T1/sl
Publication of EP2356109A2 publication Critical patent/EP2356109A2/fr
Publication of EP2356109A4 publication Critical patent/EP2356109A4/fr
Application granted granted Critical
Publication of EP2356109B1 publication Critical patent/EP2356109B1/fr
Priority to HRP20170357TT priority patent/HRP20170357T1/hr
Priority to CY20201100404T priority patent/CY1123625T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/62—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems having two or more ring systems containing condensed 1,3-oxazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
EP09820030.6A 2008-10-10 2009-10-12 Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d' autres maladies Active EP2356109B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PL09820030T PL2356109T3 (pl) 2008-10-10 2009-10-12 Kompozycje i sposoby leczenia zaburzeń używania alkoholu, bólu i innych chorób
EP16187663.6A EP3135672B9 (fr) 2008-10-10 2009-10-12 Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d' autres maladies
PL16187663T PL3135672T3 (pl) 2008-10-10 2009-10-12 Kompozycje i sposoby leczenia zaburzeń używania alkoholu, bólu i innych chorób
SI200931622A SI2356109T1 (sl) 2008-10-10 2009-10-12 Sestavki in postopki za zdravljenje motenj zaradi uživanja alkohola, bolečine in drugih bolezni
DK16187663.6T DK3135672T3 (da) 2008-10-10 2009-10-12 Sammensætninger og fremgangsmåder til behandling af alkoholforbrugslidelser, smerter og andre sygdomme
HRP20170357TT HRP20170357T1 (hr) 2008-10-10 2017-03-03 Sastavi i postupci za liječenje poremećaja zbog konzumacije alkohola, bolova i ostalih bolesti
CY20201100404T CY1123625T1 (el) 2008-10-10 2020-05-04 Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10467208P 2008-10-10 2008-10-10
PCT/US2009/060367 WO2010042925A2 (fr) 2008-10-10 2009-10-12 Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d'autres maladies

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP16187663.6A Division-Into EP3135672B9 (fr) 2008-10-10 2009-10-12 Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d' autres maladies
EP16187663.6A Division EP3135672B9 (fr) 2008-10-10 2009-10-12 Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d' autres maladies

Publications (3)

Publication Number Publication Date
EP2356109A2 EP2356109A2 (fr) 2011-08-17
EP2356109A4 true EP2356109A4 (fr) 2012-05-30
EP2356109B1 EP2356109B1 (fr) 2016-12-07

Family

ID=42101255

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09820030.6A Active EP2356109B1 (fr) 2008-10-10 2009-10-12 Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d' autres maladies
EP16187663.6A Active EP3135672B9 (fr) 2008-10-10 2009-10-12 Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d' autres maladies

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP16187663.6A Active EP3135672B9 (fr) 2008-10-10 2009-10-12 Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d' autres maladies

Country Status (13)

Country Link
US (1) US8729081B2 (fr)
EP (2) EP2356109B1 (fr)
CN (2) CN102177153B (fr)
CY (2) CY1118665T1 (fr)
DK (2) DK2356109T3 (fr)
ES (2) ES2617873T3 (fr)
HR (2) HRP20170357T1 (fr)
HU (2) HUE050319T2 (fr)
LT (2) LT3135672T (fr)
PL (2) PL2356109T3 (fr)
PT (2) PT2356109T (fr)
SI (2) SI2356109T1 (fr)
WO (1) WO2010042925A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2356109T3 (en) 2008-10-10 2017-03-13 Vm Discovery Inc COMPOSITIONS AND PROCEDURES FOR TREATING DISEASES IN CONNECTION WITH ALCOHOL CONSUMPTION, Pain and OTHER DISEASES
AU2011313853A1 (en) 2010-10-11 2013-05-02 Auckland Uniservices Limited Substituted benzamides and their uses
JP2014522396A (ja) * 2011-05-27 2014-09-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 置換２−ベンジリデン−２Ｈ−ベンゾ［ｂ］［１，４］チアジン−３（４Ｈ）−オン、その誘導体及びその治療上の使用
WO2013043985A1 (fr) 2011-09-23 2013-03-28 The Regents Of The University Of California Huiles comestibles favorisant l'administration de stéroïdes administrés par voie orale
CN104736158A (zh) 2012-01-23 2015-06-24 萨奇治疗股份有限公司 神经活性类固醇制剂和治疗中枢神经系统障碍的方法
RU2014141510A (ru) * 2012-04-12 2016-06-10 Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити Замещенные бензамиды и их применения, перекрестная ссылка на связанные заявки
RU2667010C2 (ru) 2012-08-21 2018-09-13 Сейдж Терапьютикс, Инк. Способы лечения эпилепсии или эпилептического статуса
EP2906221B1 (fr) * 2012-10-11 2019-05-15 Southern Research Institute Dérivés urée et amide d'aminoalkylpipérazines et leur utilisation
EP4335505A3 (fr) 2012-11-30 2024-06-05 The Regents of The University of California Activité anticonvulsivante de stéroïdes
JP6426694B2 (ja) 2013-03-15 2018-11-21 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビンの修飾のための化合物及びその使用
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
US9676757B2 (en) 2014-02-27 2017-06-13 Merck Patent Gmbh Heterocyclic compounds as NaV channel inhibitors and uses thereof
US10202367B2 (en) * 2014-06-12 2019-02-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Heterocyclic compounds and methods of use thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
JP6838074B2 (ja) 2016-03-08 2021-03-03 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
ES2696516B2 (es) * 2017-07-12 2019-06-19 Consejo Superior Investigacion Compuestos derivados de piperidina como inhibidores de PDE8A
EP3886854A4 (fr) 2018-11-30 2022-07-06 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
MX2022013838A (es) 2020-05-04 2023-02-22 Amgen Inc Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso.
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008411A1 (fr) * 2001-07-19 2003-01-30 Cv Therapeutics, Inc. Composes de piperazine substitues et leur utilisation en tant qu'inhibiteurs de l'oxydation d'acides gras
EP1394154A1 (fr) * 2001-03-23 2004-03-03 Takeda Chemical Industries, Ltd. Derive heterocyclique a cinq membres d'acide alcanoique
WO2005039549A1 (fr) * 2003-10-27 2005-05-06 Novartis Ag Derives d'indolyle-pyrroledione pour traiter des troubles neurologiques et vasculaires lies a la generation et/ou a l'agregation de beta-amyloide
EP1541564A1 (fr) * 2002-09-10 2005-06-15 Takeda Pharmaceutical Company Limited Composes heterocycliques a cinq elements
WO2005082367A1 (fr) * 2004-02-18 2005-09-09 Devgen Nv Inhibiteurs de kinase
WO2005097786A1 (fr) * 2004-04-01 2005-10-20 Sanofi-Aventis Deutschland Gmbh Derives d'oxadiazolone utilises en tant qu'agonistes delta ppar
WO2006103045A1 (fr) * 2005-03-31 2006-10-05 Ucb Pharma S.A. Composes comprenant un groupe fonctionnel d'oxazole ou de thiazole, processus de fabrication et leur utilisation
WO2007006546A1 (fr) * 2005-07-11 2007-01-18 Devgen N.V. Derives d'amide utilises comme inhibiteurs des kinases
WO2007107758A1 (fr) * 2006-03-23 2007-09-27 Prolysis Ltd Agents antibactériens
WO2008006043A2 (fr) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Dérivés d'acide substitués pouvant être employés en tant qu'agents anti-athérosclérotiques, anti-dyslipidémiques, anti-diabétiques et anti-obésité, et méthode
EP1897872A1 (fr) * 2005-05-25 2008-03-12 Nippon Chemiphar Co., Ltd. Activateur pour les recepteurs actives par les proliferateurs des peroxysomes
WO2008038841A1 (fr) * 2006-09-30 2008-04-03 Japan Tobacco Inc. Dérivé de thiadiazolone et utilisation de celui-ci
EP1911738A1 (fr) * 2005-07-29 2008-04-16 Takeda Pharmaceutical Company Limited Composé de l acide phénoxyalkanoique
WO2008117982A1 (fr) * 2007-03-28 2008-10-02 Crystal Genomics, Inc. Dérivés d'acide carboxylique hétérocyclique et composition pharmaceutique les contenant pour inhiber l'accumulation des lipides
WO2009042294A2 (fr) * 2007-08-10 2009-04-02 Burnham Institute For Medical Research Activateurs de la phosphatase alcaline non spécifique des tissus (tnap) et leurs utilisations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2711655A1 (de) * 1977-03-17 1978-09-21 Basf Ag Pyridinyl-aminoalkylaether
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
JP2002053566A (ja) * 2000-08-11 2002-02-19 Japan Tobacco Inc チアゾール化合物及びその医薬用途
BR0212510A (pt) * 2001-09-14 2004-08-24 Methylgene Inc Inibidor de histona desacetilase, composto e composição
US7868204B2 (en) 2001-09-14 2011-01-11 Methylgene Inc. Inhibitors of histone deacetylase
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
AU2002361096A1 (en) * 2001-12-27 2003-07-15 Sumitomo Pharmaceuticals Company, Limited Hydroxamic acid derivative and mmp inhibitor containing the same as active ingredient
US20050038078A1 (en) * 2003-08-11 2005-02-17 Agouron Pharmaceuticals, Inc. Antiproliferative 2-(heteroaryl)-aminothiazole compounds and pharmaceutical compositions, and methods for their use
US7514566B2 (en) * 2006-01-18 2009-04-07 Amgen, Inc. Thiazole compounds and methods of use
WO2008053863A1 (fr) * 2006-10-30 2008-05-08 Santen Pharmaceutical Co., Ltd. Nouveau composé ayant un squelette de 1,4-benzothiazin-3-one ou un squelette de 3,4-dihydroquinolin-2-one
WO2008053861A1 (fr) * 2006-10-30 2008-05-08 Santen Pharmaceutical Co., Ltd. Nouveau composé ayant un squelette 1,4-benzoxazin-3-one
EP2219646A4 (fr) * 2007-12-21 2010-12-22 Univ Rochester Procédé permettant de modifier la durée de vie d'organismes eucaryotes
DK2356109T3 (en) 2008-10-10 2017-03-13 Vm Discovery Inc COMPOSITIONS AND PROCEDURES FOR TREATING DISEASES IN CONNECTION WITH ALCOHOL CONSUMPTION, Pain and OTHER DISEASES
JP6643807B2 (ja) 2015-03-09 2020-02-12 キヤノン株式会社 文書管理クライアント装置、文書管理方法

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1394154A1 (fr) * 2001-03-23 2004-03-03 Takeda Chemical Industries, Ltd. Derive heterocyclique a cinq membres d'acide alcanoique
WO2003008411A1 (fr) * 2001-07-19 2003-01-30 Cv Therapeutics, Inc. Composes de piperazine substitues et leur utilisation en tant qu'inhibiteurs de l'oxydation d'acides gras
EP1541564A1 (fr) * 2002-09-10 2005-06-15 Takeda Pharmaceutical Company Limited Composes heterocycliques a cinq elements
WO2005039549A1 (fr) * 2003-10-27 2005-05-06 Novartis Ag Derives d'indolyle-pyrroledione pour traiter des troubles neurologiques et vasculaires lies a la generation et/ou a l'agregation de beta-amyloide
WO2005082367A1 (fr) * 2004-02-18 2005-09-09 Devgen Nv Inhibiteurs de kinase
WO2005097786A1 (fr) * 2004-04-01 2005-10-20 Sanofi-Aventis Deutschland Gmbh Derives d'oxadiazolone utilises en tant qu'agonistes delta ppar
WO2006103045A1 (fr) * 2005-03-31 2006-10-05 Ucb Pharma S.A. Composes comprenant un groupe fonctionnel d'oxazole ou de thiazole, processus de fabrication et leur utilisation
EP1897872A1 (fr) * 2005-05-25 2008-03-12 Nippon Chemiphar Co., Ltd. Activateur pour les recepteurs actives par les proliferateurs des peroxysomes
WO2007006546A1 (fr) * 2005-07-11 2007-01-18 Devgen N.V. Derives d'amide utilises comme inhibiteurs des kinases
EP1911738A1 (fr) * 2005-07-29 2008-04-16 Takeda Pharmaceutical Company Limited Composé de l acide phénoxyalkanoique
WO2007107758A1 (fr) * 2006-03-23 2007-09-27 Prolysis Ltd Agents antibactériens
WO2008006043A2 (fr) * 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Dérivés d'acide substitués pouvant être employés en tant qu'agents anti-athérosclérotiques, anti-dyslipidémiques, anti-diabétiques et anti-obésité, et méthode
WO2008038841A1 (fr) * 2006-09-30 2008-04-03 Japan Tobacco Inc. Dérivé de thiadiazolone et utilisation de celui-ci
WO2008117982A1 (fr) * 2007-03-28 2008-10-02 Crystal Genomics, Inc. Dérivés d'acide carboxylique hétérocyclique et composition pharmaceutique les contenant pour inhiber l'accumulation des lipides
WO2009042294A2 (fr) * 2007-08-10 2009-04-02 Burnham Institute For Medical Research Activateurs de la phosphatase alcaline non spécifique des tissus (tnap) et leurs utilisations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 10 August 2006 (2006-08-10), XP002672241, Database accession no. 902619-02-7 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 12 October 2007 (2007-10-12), XP002672245, Database accession no. 950436-85-8 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 16 August 2006 (2006-08-16), XP002672242, Database accession no. 901716-44-7 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 19 September 2008 (2008-09-19), XP002672244, Database accession no. 1050553-20-2 *
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 22 August 2008 (2008-08-22), XP002672243, Database accession no. 1016358-28-3 *

Also Published As

Publication number Publication date
PT2356109T (pt) 2017-03-10
LT2356109T (lt) 2017-03-27
WO2010042925A2 (fr) 2010-04-15
PT3135672T (pt) 2020-04-02
CN106243100A (zh) 2016-12-21
EP2356109B1 (fr) 2016-12-07
EP3135672A1 (fr) 2017-03-01
ES2617873T3 (es) 2017-06-20
DK2356109T3 (en) 2017-03-13
HRP20170357T1 (hr) 2017-05-05
CY1118665T1 (el) 2017-07-12
ES2782376T3 (es) 2020-09-14
US8729081B2 (en) 2014-05-20
CN102177153A (zh) 2011-09-07
SI3135672T1 (sl) 2020-07-31
PL3135672T3 (pl) 2020-11-16
HUE050319T2 (hu) 2020-11-30
PL2356109T3 (pl) 2017-07-31
HUE033711T2 (en) 2017-12-28
EP2356109A2 (fr) 2011-08-17
CY1123625T1 (el) 2022-03-24
CN106243100B (zh) 2019-04-09
LT3135672T (lt) 2020-05-25
SI2356109T1 (sl) 2017-04-26
WO2010042925A3 (fr) 2010-07-29
EP3135672B1 (fr) 2020-02-19
HRP20200552T1 (hr) 2020-07-10
US20110301149A1 (en) 2011-12-08
EP3135672B9 (fr) 2020-05-20
CN102177153B (zh) 2016-09-21
DK3135672T3 (da) 2020-05-04

Similar Documents

Publication Publication Date Title
SI3135672T1 (sl) Sestavki in postopki za zdravljenje motenj, bolečin in drugih bolezni povezanih z uporabo alkohola
EP2176283A4 (fr) Methodes et compositions de traitement des maladies cerebrales
EP2260109A4 (fr) Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate
HK1158172A1 (en) Compounds for treating ophthalmic diseases and disorders
IL202424A (en) Telomerase activator compounds for use in the treatment of disorders and related conditions
PL2349231T3 (pl) Kompozycje i metody leczenia chorób kopyta
HK1245679A1 (zh) 用於治療皮膚疾病和病症的方法和組合物
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
ZA201100459B (en) Combination of pilocarpin and methimazol for treating charcot-marietooth disease and related disorders
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
EP2274411A4 (fr) Compositions de xanthohumol et procédés de traitement des maladies ou des affections cutanées
EP2217238A4 (fr) Procédés et compositions pour le traitement de maladies protéinuriques
HK1149545A1 (en) Compositions and methods for treating ophthalmic diseases
HK1232162A1 (zh) 治療疼痛症狀及其它失調的化合物
IL213703A0 (en) Compounds and methods for the treatment of pain and other diseases
GB0822158D0 (en) Method,composition and device for the treatment of enzymes and saccharides disorders
EP2515925A4 (fr) Compositions et méthodes pour prévenir et traiter les maladies et les troubles de santé induits par l'environnement
GB0822486D0 (en) Compounds for use in the treatment of pain
EP2654434A4 (fr) Procédés pour le traitement de maladies, troubles et lésions dentaires
HK1165280A1 (zh) 芐達明在治療 依賴性疾病中的用途
PT2278962E (pt) Métodos para o tratamento de desordens dermatológicas
EP2432322A4 (fr) Compositions et méthodes de traitement optimales d'affections et de douleurs bucco-dentaires
GB0814043D0 (en) The treatment of skin disorders
GB0716834D0 (en) New formulation for treatment of skin disorders
GB0616122D0 (en) Formulation for treatment of skin disorders

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110510

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WU, JAY JIE-QIANG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VM DISCOVERY, INC.

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 279/14 20060101ALI20120416BHEP

Ipc: C07D 401/02 20060101ALI20120416BHEP

Ipc: A61K 31/4162 20060101ALI20120416BHEP

Ipc: C07D 241/40 20060101ALI20120416BHEP

Ipc: C07D 487/04 20060101ALI20120416BHEP

Ipc: C07D 265/36 20060101ALI20120416BHEP

Ipc: A61P 35/00 20060101ALI20120416BHEP

Ipc: C07D 401/14 20060101AFI20120416BHEP

Ipc: C07D 498/04 20060101ALI20120416BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120426

17Q First examination report despatched

Effective date: 20130517

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160219

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160707

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 851583

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009042972

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161207

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20170357

Country of ref document: HR

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2356109

Country of ref document: PT

Date of ref document: 20170310

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20170303

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20170309

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20161207

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E013344

Country of ref document: EE

Effective date: 20170302

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20170357

Country of ref document: HR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2617873

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170620

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20170400639

Country of ref document: GR

Effective date: 20170804

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009042972

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

26N No opposition filed

Effective date: 20170908

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E033711

Country of ref document: HU

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20170357

Country of ref document: HR

Payment date: 20190920

Year of fee payment: 11

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 851583

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161207

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20170357

Country of ref document: HR

Payment date: 20200923

Year of fee payment: 12

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20170357

Country of ref document: HR

Payment date: 20210923

Year of fee payment: 13

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20170357

Country of ref document: HR

Payment date: 20220921

Year of fee payment: 14

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20170357

Country of ref document: HR

Payment date: 20230919

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230928

Year of fee payment: 15

Ref country code: SM

Payment date: 20230926

Year of fee payment: 15

Ref country code: RO

Payment date: 20230922

Year of fee payment: 15

Ref country code: MC

Payment date: 20230921

Year of fee payment: 15

Ref country code: EE

Payment date: 20230920

Year of fee payment: 15

Ref country code: CZ

Payment date: 20230925

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20230919

Year of fee payment: 15

Ref country code: PT

Payment date: 20230926

Year of fee payment: 15

Ref country code: PL

Payment date: 20230926

Year of fee payment: 15

Ref country code: NL

Payment date: 20231026

Year of fee payment: 15

Ref country code: HR

Payment date: 20230919

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20230919

Year of fee payment: 15

Ref country code: LV

Payment date: 20230919

Year of fee payment: 15

Ref country code: LU

Payment date: 20231027

Year of fee payment: 15

Ref country code: LT

Payment date: 20230919

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20231027

Year of fee payment: 15

Ref country code: GB

Payment date: 20231027

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231102

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20231011

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20230920

Year of fee payment: 15

Ref country code: SE

Payment date: 20231027

Year of fee payment: 15

Ref country code: NO

Payment date: 20231027

Year of fee payment: 15

Ref country code: IT

Payment date: 20231023

Year of fee payment: 15

Ref country code: IE

Payment date: 20231027

Year of fee payment: 15

Ref country code: HU

Payment date: 20230927

Year of fee payment: 15

Ref country code: FR

Payment date: 20231025

Year of fee payment: 15

Ref country code: FI

Payment date: 20231025

Year of fee payment: 15

Ref country code: DK

Payment date: 20231027

Year of fee payment: 15

Ref country code: DE

Payment date: 20231027

Year of fee payment: 15

Ref country code: CY

Payment date: 20230920

Year of fee payment: 15

Ref country code: CH

Payment date: 20231102

Year of fee payment: 15

Ref country code: BG

Payment date: 20231018

Year of fee payment: 15

Ref country code: AT

Payment date: 20230920

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20231027

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20230919

Year of fee payment: 15